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INTRODUCTION
One of the primary purposes of vaccination against 
hepatitis B virus （HBV） in adults is prevention of ful-
minant hepatitis as part of preventive measures 
against for those who are associated to healthcare and 
with occupational hazards 1～3）. Given the increasing 
incidence of horizontally transmitted acute hepatitis, 
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SUMMARY
Objective：To investigate the significance of additional hepatitis B （HB） vaccination in medical students 
who were unresponsive to a primary vaccine series or those who had lost antibody to hepatitis B surface 
antigen （anti-HBs）.
Methods：Subjects were followed up for 3 years after completion of a primary HB vaccine series. One 
additional dose was given to those who lost the anti-HBs within 3 years after the initial series, while 3 
doses were given to those who had not responded to the initial vaccination. Subjects：100 medical students 
（59 men and 41 women；mean age on admission to university, 19.4±1.6 years） enrolled at the School of 
Medicine, Dokkyo Medical University in April 2012.
Results：The rate of positivity for anti-HBs was 98％ soon after completion of the primary HB vaccine 
series and decreased without the need for additional vaccination to 79％ , 61％ , and 55％ at 1, 2, and 3 
years after the primary series, respectively. Eighteen vaccinated subjects （18％） lost the anti-HBs 2 years 
after the primary series, and all of them responded to 1 additional dose. Another 18 successfully vaccinated 
subjects （18％） were anti-HBs negative both 1 and 2 years after the primary series；17 of them respond-
ed to 1 additional dose. As for 2 subjects （2％） who were unresponsive to the primary series, 1 became 
anti-HBs-positive for the first time after 3 additional doses given 2 years after the primary series.
Conclusion：A number of students became or remained anti-HBs negative after the primary HB vacci-
nation, indicating that its timing and dose of additional vaccination need to be studied further to evaluate 
its utility.
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prevention of acute hepatitis caused by genotype A, 
which has a tendency for chronicity, is of interest 4,5）. 
It is particularly necessary to prevent the onset of de 
novo hepatitis B, which carries a poor prognosis and 
often occurs after administration of immunosuppres-
sive therapy or chemotherapy in patients with a pre-
vious history of HBV infection 6,7）. HB vaccination is 
also important in the prevention of post-transfusion 
hepatitis.
In this study, we examined the levels of anti-HBs 
during a 3-year period after completion of a primary 
HB vaccine series in medical students enrolled at the 
School of Medicine, Dokkyo Medical University. Addi-
t ional HB vaccination was given to those who 
appeared to require revaccination before starting the 
clinical training in their fifth year at our medical uni-
versity and the benefits of additional HB vaccination 
was assessed.
MATERIALS AND METHODS
Subjects were 100 medical students （59 men and 
41 women；mean age on admission to university, 19.4
±1.6 years） who were negative for both hepatitis B 
surface antigen （HBsAg） and anti-HBs at the time of 
enrollment at the School of Medicine, Dokkyo Medical 
University in April, 2012. They underwent a primary 
HB vaccine series （3 shots：0 months, 1 month, and 
then 5 months） and were followed for a 3-year period 
after the primary vaccine series.
Additional doses were given to fourth-year stu-
dents who required additional vaccination before 
starting clinical training in their fifth year. Further-
more, 1 additional dose was given to those who had 
tested positive for anti-HBs after the primary vaccine 
series but who then became negative year later and 
remained negative 2 years after the primary series, or 
to those who lost anti-HBs 2 years after the primary 
series. Also three additional doses were given to those 
who had not responded to the initial vaccination, and 
had remained unresponsive for 2 years.
All subjects received Bimmugen® （The Chemo-
Sero-Therapeutic Research Institute, Kumamoto, 
Japan）, a yeast-derived recombinant, adsorbed HB 
vaccine. A series of 3 doses （10 µg in 0.5 mL/dose） 
was administered subcutaneously, and the rates of 
anti-HBs positivity were examined. Additional vacci-
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Figure 1
Grouping of subjects by anti-HBs status （n＝100）. Anti-HBs status in 100 medical students was monitored for 3 years 
after completion of the primary vaccine series. This flowchart depicts the grouping. hepatitis B：HB；antibody to hepati-
tis B surface antigen：anti-HBs.
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nation were administered in a similar manner if neces-
sary when the students were in their fourth year. 
Chemiluminescent immunoassay （CLIA） was per-
formed to determine the levels of anti-HBs at 
4 months, 1 year, 2 years, and 3 years after the prima-
ry vaccine series. Levels of anti-HBs ≥ 10 mIU/mL 
were considered positive. Results were expressed as 
mean±standard deviation （SD） or median±standard 
error of the mean （SEM）.
This study was approved by the institutional 
review board of Dokkyo Medical University, and all 
study participants had provided their informed con-
sent. All procedures were in accordance with the Dec-
laration of Helsinki.
RESULTS
1 . Grouping of subjects by anti-HBs status and 
additional HB vaccine dose are shown in Figure 1.
Anti-HBs status in 100 medical students was moni-
tored for 3 years after completion of the primary vac-
cine series. This flowchart depicts the grouping pro-
cess.
2. Figure 2 shows the changes in HBs-positive rate 
（Figure 2A） and HBs titer （Figure 2B） in primary 
vaccine series responders who remained anti-HBs 
positive for 3 years after completion of the primary 
vaccine series are shown here.
The rate of positivity for anti-HBs was 98％ in the 
same year of the primary HB vaccine series and then 
decreased without the need of additional vaccination 
to 79％ , 61％ , and 55％ at 1, 2, and 3 years after the 
primary series, respectively. Thus, 55％ of subjects 
retained their seropositive status after the primary 
series and retained their anti-HBs-positive status 
throughout a 3-year follow-up period （Figure 2A）. 
Changes in anti-HBs titer were shown in Figure 2B.
3 . Figure 3 shows the changes in HBs titer in 6 
responders to the primary vaccine series who 
remained anti-HBs positive for 2 years but became 
anti-HBs negative on 3rd year after completion of the 
primary vaccine series.
4 . Figure 4 shows the changes in HBs titer in 
responders to the primary vaccine series who became 
anti-HBs negative and had received one additional 
dose 2 years after completion of the primary vaccine 
series. All 18 subjects responded to the additional 
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Figure 2
Changes in the HBs-positive rate （A） and HBs titer （B） in responders to the primary vaccine series who 
remained anti-HBs positive for 3 years after completion of the primary vaccine series.
Cut-off value of anti-HBs titer：10 mIU/mL. Anti-HBs titers expressed as median±standard error of the 
mean （SEM）.
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dose and seroconverted to anti-HBs positive again.
5 . One male subject became anti-HBs-positive 
（159.4 mIU/mL） after the primary vaccine series, but 
switched between positive and negative at each test 
time point：negative （8.1 mIU/mL）, positive without 
an additional dose （21.3 mIU/mL）, and then negative 
（3.9 mIU/mL） at 1, 2, and 3 years after the primary 
series, respectively as shown in Figure 5.
6 . Figure 6 shows the changes in HBs titer in 
responders to the primary vaccine series who became 
anti-HBs negative in the following year, remained 
negative, and received an additional dose 2 years after 
completion of the primary vaccine series. Seventeen of 
18 subjects responded to the additional dose and sero-
converted to anti-HBs positive again （Figure 6A）. 
Conversely, one male subject became anti-HBs-posi-
tive （25.7 mIU/mL） after the primary series, reverted 
to negative （4.7 mIU/mL） 1 year after the primary 
vaccine series, and then remained negative （1.4 mIU/
mL） the following year. The subject did not respond 
to 1 additional dose, and remained anti-HBs-negative 
（8.4 mIU/mL） 3 years after the primary series （Fig-
ure 6 B）.
7. Figure 7 shows the changes in HBs titer in non-
responders to the primary vaccine series who 
remained anti-HBs negative for 2 years and then 
received 3 additional doses.
One male subject remained anti-HBs-negative in 
the same year of the primary vaccine series （5.9 mIU/
mL）, and at 1 and 2 years after the primary series 
（1 .4 mIU/mL and 1 .0 mIU/mL, respectively）. He 
became seropositive for the first time at 3 years after 
3 additional doses （45.2 mIU/mL） （Figure 7, case 1）. 
However, HBs titer remained negative even after 3 
additional doses were administered in the other sub-
ject （Figure 7, case 2）.
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Figure 4
Changes in HBs titer in 18 responders to the primary 
vaccine series who became anti-HBs negative and had 
received one additional dose 2 years after the completion 
of the primary vaccine series. All 18 subjects responded 
to the additional dose and seroconverted to become anti-
HBs positive again. Cut-off value of anti-HBs titer：
10 mIU/mL. Data expressed as median±SEM.
Figure 3
Changes in HBs titer in 6 responders to the primary vac-
cine series who remained anti-HBs positive for 2 years 
but became negative on 3rd year after completion of the 
primary vaccine series. Cut-off value of anti-HBs titer：
10 mIU/mL. Data expressed as median±SEM.
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DISCUSSION
HB vaccination of infants born to mothers who are 
HBV carriers is crucial in preventing vertical trans-
mission 8,9）. Also, given the risks of horizontal transmis-
sion present in daily life settings, such as intrafamilial 
transmission （including father-to-child transmission） 
and mass infection in nurseries during infancy 10）. It is 
therefore, the need of HB vaccination is an essential 
preventive measure. Risk of transmission of HBV, 
hepatitis C virus （HCV）, and human immunodeficien-
cy virus （HIV） was 30％ , 1.8％ , and 0.3％ , respec-
tively, clearly showing that the risk of HBV transmis-
sion is remarkably high 1,2）.
Universal vaccination of infants ＜1 year old against 
HBV was finally introduced in Japan in 2016. Howev-
er, voluntary HB vaccination programs for adults in 
high-risk groups are necessary until all citizens have 
benefited from this newly introduced vaccination pro-
gram.
HB vaccination in adults is an essential preventive 
measure against healthcare-associated HBV infections 
in people, who are directly involved in healthcare 
（such as doctors and nurses）, and against occupation-
al infections in those at risk of exposure to infected 
blood and/or other body fluids （including hospital 
housekeeping, room cleaning, and laundry staff）10）. It 
is also important in preventing post-transfusion hepa-
titis B. With the trend of increasing cases of horizon-
tally transmitted acute hepatitis B, prevention of 
acute hepatitis caused by genotype A with its tenden-
cy for chronicity is particularly necessary 11～15）. Also, 
it is important to prevent the onset of de novo hepati-
tis B, which carries a poor prognosis and usually 
occurs after immunosuppressive therapy or chemo-
therapy in patients with a previous history of HBV 
infection 16～18）. 
Changes in anti-HBs levels after HB vaccination 
were previously examined 19～21）. The minimum protec-
tive anti-HBs level is 10 mIU/mL as determined by 
the World Health Organization （WHO） reference 
preparations, and this was the threshold value used in 
this study.
Our study showed that the primary vaccine series 
achieved an anti-HBs positivity rate of 98％；the 
rates of positivity after year 1, 2 and 3 were 79％ , 61
％ , and 55％ , respectively. Thus, 55％ of the subjects 
remained anti-HBs positive throughout the 3-year fol-
low-up period （Figure 2A）. Variation in immune 
response is thought to have been a major contributing 
factor to the difference between those who retained 
anti-HBs positivity and those who lost this status 22）. 
There are several possible types of changes in anti-
HBs levels including the persistent high level, the 
high-to-low level, the persistent low level, and the 
low-to-negative level types. We will continue to moni-
tor anti-HBs levels at routine health checks to 
observe the changes in vaccinated students.
In this study, 1 male student lost, regained, and then 
lost anti-HBs -positive status 1 year, 2 years, and 3 
years after the primary vaccine series, respectively 
（Figure 5）. Although the possibility of a new infection 
cannot be eliminated, fluctuation of anti-HBs measure-
ments may not be negligible around the positive/neg-
ative threshold.
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Figure 5
One male subject who lost anti-HBs 1 year after primary 
vaccine series, regained antibodies without an additional 
dose at 2 years, and then lost his positive status again at 
3 years. Cut-off value of anti-HBs titer：10 mIU/mL.
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We found 3 additional dose patterns. The first pat-
tern involved a single additional dose given to 18 sub-
jects （18％） who retained vaccine-induced anti-HBs 
positivity 1 year after, but lost it 2 years after the pri-
mary vaccine series. All 18 subjects regained the 
anti-HBs positive status after receiving one additional 
dose （Figure 4）. The second pattern was that of a 
single additional dose given to 18 subjects （18％） who 
lost their anti-HBs positive status 1 year after, and 
still remained negative 2 years after the primary 
series. Seventeen （17％） of these subjects regained 
the anti-HBs positive status after a single additional 
dose （Figure 6A）, but 1 （1％） did not respond （Fig-
ure 6B）. A single additional dose may not be sufficient 
to regain immunity against HBV in those with anti-
HBs levels around the lower range of positivity after 
the primary series. The third pattern was of 3 addi-
tional doses given to 2 subjects （2％） who did not 
test positive for anti-HBs during the 2-year period 
after the primary series. One of these subjects 
became anti-HBs-positive for the first time after 
receiving 3 additional doses （Figure 7, case 1）, sug-
gesting the benefit of additional doses to those who 
were previously unresponsive. However, another sub-
ject still remained anti-HBs negative （Figure 7, case 
2）. Further study is warranted to determine the dif-
ference between case 1 and case 2.
In non-responsive vaccinated students who did not 
become seropositive, general countermeasures applica-
ble to those unresponsive to HB vaccination consist of 
giving a normal 3-shot HB vaccine series a year later, 
changing the route of administration from subcutane-
ous to intramuscular, or changing the type of vac-
cine 23～25）. However, the most effective method has not 
yet been identified, and this needs to be examined in 
future.
55％ of students who acquired anti-HBs-positive 
after the primary vaccine series retained antibodies 
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Figure 6
Changes in HBs titer in responders to the primary vaccine series who became anti-HBs negative the following 
year and remained negative and received an additional dose 2 years after completion of the primary vaccine 
series.
A：Changes in HBs titer in those who became anti-HBs positive after the additional dose （17 cases）.
B：Changes in HBs titer in those who remained anti-HBs negative after the additional dose （1 case）.
Cut-off value of anti-HBs titer：10 mIU/mL. Data expressed as median±SEM.
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throughout a 3-year observation period. The United 
States Centers for Disease Control and Prevention 
（CDC） does not include individuals who lost acquired 
antibodies in the group requiring booster doses 26）. 
However, in 2011 , Stramer et al.27） reported that 
patients who had received HB vaccination tested neg-
ative for HBsAg and showed no increase in alanine 
aminotransferase （ALT） level；however, they consis-
tently tested positive for HBV DNA and immunoglob-
ulin M antibody to hepatitis B core antigen （IgM 
anti-HBc） after secondary exposure to HBV, suggest-
ing a new infection in individuals with low levels of 
anti-HBs.
In conclusion, as medical students are at high risk 
of HBV infection, especially during clinical training, 
seropositive status via HB vaccination is needed. 
Either three additional doses or one additional dose 
were given to fourth-year medical students who did 
not respond to the primary vaccine series or who 
responded but became anti-HBs negative before start-
ing their fifth-year clinical training, respectively. After 
the additional doses, most of these students became 
anti-HBs positive. These findings suggest that addi-
tional doses of HB vaccine are necessary. However, 9 
fifth-year students were anti-HBs negative （Figure 
3：6 cases；Figure 5：1case；Figure 6B：1 case；
Figure 7：1 case）, indicating that the timing and dose 
of additional HB vaccination needs to be studied fur-
ther to evaluate its efficacy.
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